ArticleScientific reports2022
Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 23 citations in OpenAlex.
- Lung tumour secretome and extracellular vesicles: mechanisms, biomarkers, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Immune Regulation and the Role of Extracellular Vesicles in Non-Small Cell Lung Cancer: Biological Mechanisms and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multifaceted Role of Extracellular Vesicles: Intercellular Messengers to Therapeutic Applications: A Narrative Review.Health science reports · 2026Review
- Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer.bioRxiv : the preprint server for biology · 2026Article
- TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients.Translational lung cancer research · 2026Article
- Review
- Extracellular vesicles in pulmonary diseases: roles and therapeutic potential.BMC pulmonary medicine · 2025Review
- Sorafenib generates microvesicle particles in non-small cell lung cancer.Tumor discovery · 2025Article
- Capture and detection of extracellular vesicles derived from human breast cancer cells using a 3D self-assembled nanostructured SiOJournal of biological engineering · 2025Article
- Extracellular Vesicles in cancer: from isolation and characterization to metastasis, drug resistance, and clinical applications.BMC cancer · 2025Review
- Whispers in the Lungs: Small Extracellular Vesicles in Lung Cancer and COPD Crosstalk.Cancers · 2025Review
- Lung cancer exosomal Gal3BP promotes osteoclastogenesis with potential connotation in osteolytic metastasis.Scientific reports · 2024Article
- Construction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer.Discover oncology · 2024Article
- Downregulation of 4-HNE and FOXO4 collaboratively promotes NSCLC cell migration and tumor growth.Cell death & disease · 2024Article
- Modulating tumoral exosomes and fibroblast phenotype using nanoliposomes augments cancer immunotherapy.Science advances · 2024Article
- Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly.Nature communications · 2024Article
- Trace Sample Proteome Quantification by Data-Dependent Acquisition without Dynamic Exclusion.Analytical chemistry · 2023Article
- Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry.Journal of visualized experiments : JoVE · 2023Article
- Organic Electronic Platform for Real-Time Phenotypic Screening of Extracellular-Vesicle-Driven Breast Cancer Metastasis.Advanced healthcare materials · 2023Article
- The protein and miRNA profile of plasma extracellular vesicles (EVs) can distinguish feline mammary adenocarcinoma patients from healthy feline controls.Scientific reports · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Extracellular vesicles (EVs) released from non-small cell lung cancer (NSCLC) cells are known to promote cancer progression. However, it remains unclear how EVs from various NSCLC cells differ in their secretion profile and their ability to promote phenotypic changes in non-tumorigenic cells. Here, we performed a comparative analysis of EV release from non-tumorigenic cells (HBEC/BEAS-2B) and several NSCLC cell lines (A549, H460, H358, SKMES, and Calu6) and evaluated the potential impact of NSCLC EVs, including EV-encapsulated RNA (EV-RNA), in driving invasion and epithelial barrier impairment in HBEC/BEAS-2B cells. Secretion analysis revealed that cancer cells vary in their secretion level, with some cell lines having relatively low secretion rates. Differential uptake of NSCLC EVs was also observed, with uptake of A549 and SKMES EVs being the highest. Phenotypically, EVs derived from Calu6 and H358 cells significantly enhanced invasion, disrupted an epithelial barrier, and increased barrier permeability through downregulation of E-cadherin and ZO-1. EV-RNA was a key contributing factor in mediating these phenotypes. More nuanced analysis suggests a potential correlation between the aggressiveness of NSCLC subtypes and the ability of their respective EVs to induce cancerous phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.